BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6582678)

  • 21. Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin.
    Seipelt G; Hofmann WK; Martin H; Wassmann B; Boehme A; Ottmann OG; Hoelzer D
    Ann Hematol; 1998; 76(3-4):145-51. PubMed ID: 9619732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the Childrens Cancer Study Group.
    Feig SA; Krailo MD; Harris RE; Baum E; Holcenberg JS; Kaizer H; Steinherz L; Pendergrass TW; Saunders EF; Warkentin PL
    Med Pediatr Oncol; 1992; 20(2):124-9. PubMed ID: 1734217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
    Chisesi T; Capnist G; de Dominicis E; Dini E
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):681-4. PubMed ID: 3164269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
    Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Idarubicin: a second-generation anthracycline.
    Fields SM; Koeller JM
    DICP; 1991 May; 25(5):505-17. PubMed ID: 2068836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
    Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; Fleischhack G; Graf N; Klingebiel T; Kremens B; Lehrnbecher T; von Neuhoff C; Ritter J; Sander A; Schrauder A; von Stackelberg A; Starý J; Reinhardt D
    Blood; 2013 Jul; 122(1):37-43. PubMed ID: 23704089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies.
    Carella AM; Berman E; Maraone MP; Ganzina F
    Haematologica; 1990; 75(2):159-69. PubMed ID: 2192943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 4-Demethoxydaunorubicin (idarubicin) in refractory or relapsed acute leukemias.
    Carella AM; Santini G; Martinengo M; Marmont AM
    Haematologica; 1984; 69(6):767-8. PubMed ID: 6441755
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase II study of idarubicin in advanced cervical carcinoma.
    Hakes TB; Dougherty JB; Raymond V
    Am J Clin Oncol; 1986 Jun; 9(3):262-3. PubMed ID: 3460321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idarubicin in combination with intermediate-dose cytarabine in the treatment of refractory or relapsed acute leukemias.
    Carella AM; Pungolino E; Piatti G; Gaozza E; Nati S; Spriano M; Giordano D; D'Amico T; Damasio E
    Eur J Haematol; 1989 Oct; 43(4):309-13. PubMed ID: 2583257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia.
    Pashko S; Jacobs J; Santorsa J
    Clin Ther; 1991; 13(3):353-60. PubMed ID: 1954636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia.
    Berman E; Raymond V; Daghestani A; Arlin ZA; Gee TS; Kempin S; Hancock C; Williams L; Stevens YW; Clarkson BD
    Cancer Res; 1989 Jan; 49(2):477-81. PubMed ID: 2910465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
    Petti MC; Mandelli F
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):10-5. PubMed ID: 2928805
    [No Abstract]   [Full Text] [Related]  

  • 35. A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
    Stuart NS; Cullen MH; Priestman TJ; Blackledge GR; Tyrrell CJ
    Cancer Chemother Pharmacol; 1988; 21(4):351-4. PubMed ID: 3163529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous and oral demethoxydaunorubicin (NSC 256-439) in the treatment of acute leukemia and lymphoma: a pilot study.
    Eridani S; Slater NG; Singh AK; Pearson TC
    Blut; 1985 Jun; 50(6):369-72. PubMed ID: 3859341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
    Berman E; Heller G; Santorsa J; McKenzie S; Gee T; Kempin S; Gulati S; Andreeff M; Kolitz J; Gabrilove J
    Blood; 1991 Apr; 77(8):1666-74. PubMed ID: 2015395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
    Vogler WR; Velez-Garcia E; Weiner RS; Flaum MA; Bartolucci AA; Omura GA; Gerber MC; Banks PL
    J Clin Oncol; 1992 Jul; 10(7):1103-11. PubMed ID: 1607916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia.
    Carella AM; Martinengo M; Santini G; Gaozza E; Damasio E; Giordano D; Nati S; Congiu A; Cerri R; Risso M
    Eur J Cancer Clin Oncol; 1987 Nov; 23(11):1673-8. PubMed ID: 3480803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Improved treatment results in children with AML: Results of study AML-BFM 93].
    Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
    Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.